Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva Pharmaceuticals (TEVA) stock is down more than 7% to start the week as the company continues to face lawsuits, leading to a downgrade.
The post Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today appeared first on InvestorPlace.

Teva Pharmaceuticals News: Why TEVA Stock Is Sliding Today

Callon Petroleum

PG&E

The indexes didn't make major moves today, but these stocks did.

Why Callon Petroleum, Teva Pharmaceutical Industries, and PG&E Slumped Today

Teva Pharmaceutical shares moved lower after Morgan Stanley downgraded the stock to Underweight with a price target of $6 per share.

Teva Relief Rally Loses Steam After Analyst Downgrade

Endo International

Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers.

Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns

Ford Motor Company

Winnebago

3 Top Value Stocks to Buy in  July

AbbVie

Bristol-Myers

Eli Lilly

Merck

Pfizer

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials.

Big Pharma Sees Rising Tide in Short Interest

Amgen

Gilead Sciences

Novo Nordisk

Sanofi

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Court Ruling Topples Trump Order, No Price Display in TV Ads

Is 3.9 times earnings cheap? Yes. But other valuation metrics tell a different story.

Teva Stock Upgraded: What You Need to Know

Noble Corp PLC

One company has lost 85% in four years, the other 95% in five years. Both look to be big-time bargains for the long term.

2 Stocks Wall Street Hates That I've Been Buying

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced trial results Tuesday that could bode well for migraine patients.

Teva's Migraine Prevention Drug Meets Exploratory Endpoints

Aurora Cannabis

B2Gold

Oasis Petroleum

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling New Stocks Under $10 With Massive Implied Upside

CenturyLink

FedEx

Golar LNG

ArcelorMittal

Schlumberger

Schneider National

These companies are going to have a tough time with the market’s heat, making each of them stocks to sell now.
The post 7 F-Rated Stocks to Sell for Summer appeared first on InvestorPlace.

7 F-Rated Stocks to Sell for Summer

Mesoblast

New Gold

Find out how a combination of factors helped these stocks defy a down market.

Why Teva Pharmaceutical Industries, Mesoblast, and New Gold Jumped Today

An Oklahoma judge on Monday approved a revised $85 million (£66.7 million) settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.

Oklahoma judge approves Teva's $85 million opioid settlement

Teva had reached an agreement with the state of Oklahoma last month, just two days before the drugmaker was set to face a trial alongside Johnson & Johnson.

Judge approves Teva's $85 million opioid settlement with state of Oklahoma

Mylan

Buying stocks that have declined to bargain levels due to negative headlines and sentiment can pay off big.

Mylan And Teva: History Shows Buying The Current Pain Could Be Your Big Future Gain

Teva's stock has reached multi-year lows and can't find steady support after the decision has been made to settle the first opioid case.

Teva: Common Law Vs. Civil Law Misperceptions Can Be Devastating

Bank of New York Mellon

Buffett-approved stocks at lower-than-Buffett's prices

2 Warren Buffett Stocks Tumble To 52-Week Lows

Teva has recently become the punching bag for a price-fixing scandal and the opioid crisis. The market has decimated the share price to multi-year lows.

Teva: Catching The Falling Knife While Blindfolded In A Maelstrom Of Headlines

TEVA's generic revenues are surprisingly resilient against Medicare reform.

Price Fixing Lawsuits And Opioid Litigation Shouldn't Deliver A Killing Blow To Teva - 100% Upside

Teva Pharmaceutical skidded to a nearly two-decade low Wednesday amid confusion over its $85 million payment to Oklahoma to settle an ongoing opioid abuse case.

Pharma Giant Nears Two-Decade Low As Opioid Settlement Remains In Limbo

Teva shares briefly reached fresh lows after an Oklahoma judge declined the company's settlement offer and requested more information.

Teva Retests Lows After Judge Declines Settlement Offer

Big Pharma Sees a Rising Tide in Short Interest

American Airlines

Immunomedics

MGM Resorts

Insider buying can be an encouraging signal for potential investors. Board chairs at pharmaceutical companies made notable buys this week.

Notable Insider Buys This Past Week

Biogen

Celgene

Novartis

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

News for Teva Pharmaceutical Stock (TEVA)